CLSD Stock Price, Clearside Biomedical Inc Quote, Chart

Market Summary

USD1.31-0.01

Market Closed

-0.76%

CLSD Alerts

1 major insider buys recently.

CLSD Stock Price

View Fullscreen

CLSD RSI Chart

CLSD Valuation

Market Cap

97.9M

Price/Earnings (Trailing)

-3.01

Price/Sales (Trailing)

11.45

Price/Free Cashflow

-4.92

CLSD Price/Sales (Trailing)

CLSD Profitability

Return on Equity

204.15%

Return on Assets

-95.49%

Free Cashflow Yield

-20.34%

CLSD Fundamentals

CLSD Revenue

Revenue (TTM)

8.6M

Rev. Growth (Yr)

1.8K%

Rev. Growth (Qtr)

638.65%

CLSD Earnings

Earnings (TTM)

-32.5M

Earnings Growth (Yr)

49.99%

Earnings Growth (Qtr)

47.86%

Breaking Down CLSD Revenue

Last 7 days

-2.2%

Last 30 days

-8.4%

Last 90 days

-4.4%

Trailing 12 Months

35.0%

How does CLSD drawdown profile look like?

CLSD Financial Health

Current Ratio

4.42

Debt/Equity

-0.02

Debt/Cashflow

-47.1

CLSD Investor Care

Shares Dilution (1Y)

21.77%

Diluted EPS (TTM)

-0.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	2.0M	2.5M	8.6M
2022	22.5M	15.5M	8.4M	1.3M
2021	13.3M	18.7M	24.2M	29.6M
2020	6.2M	6.5M	9.8M	7.9M
2019	565.8K	1.1M	1.6M	2.2M
2018	0	0	0	30.0K
2017	476.3K	432.5K	388.8K	345.0K
2016	0	0	0	520.0K
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Clearside Biomedical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	gibney anthony s	bought	121,277	1.3	93,290	-
Apr 17, 2024	gibney anthony s	bought	8,387	1.25	6,710	-
Mar 20, 2024	chong ngai hang victor	bought	48,000	1.6	30,000	chief medical officer
Feb 07, 2024	whitmore bradford t	bought	599,999	1.35	444,444	-
Jan 19, 2024	deignan charles a.	sold	-16,512	1.28	-12,900	chief financial officer
Jan 19, 2024	lasezkay george m	sold	-22,860	1.27	-18,000	ceo
Nov 01, 2023	whitmore bradford t	bought	47,901	0.7442	64,366	-
Oct 31, 2023	whitmore bradford t	bought	51,537	0.7278	70,812	-
Oct 30, 2023	whitmore bradford t	bought	411	0.685	600	-
Oct 03, 2023	hutson nancy j	bought	8,600	0.86	10,000	-

Which funds bought or sold CLSD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CREATIVE FINANCIAL DESIGNS INC /ADV	unchanged	-	36.00	153	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	unchanged	-	1.00	3.00	-%
Apr 29, 2024	Newman Dignan & Sheerar, Inc.	sold off	-100	-32,787	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-34,537	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-53.62	-5,000	8,000	-%
Apr 25, 2024	Rosalind Advisors, Inc.	new	-	3,966,670	3,966,670	3.71%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	4.76	5,000	17,000	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-2,000	-	-%
Apr 16, 2024	Stratos Wealth Advisors, LLC	unchanged	-	5,040	21,420	-%

Are Funds Buying or Selling CLSD?

Are funds buying CLSD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLSD

No. of Funds

CLSD Alerts

1 major insider buys recently.

Unveiling Clearside Biomedical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 01, 2023	whitmore bradford t	10.1%	6,264,964	SC 13G/A
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 13, 2023	carmignac gestion	3.98%	2,400,344	SC 13G/A
Jan 04, 2023	hatteras venture advisors iii, llc	0%	0	SC 13D/A
Jan 04, 2023	whitmore bradford t	9.9%	6,017,852	SC 13G/A
Feb 14, 2022	rtw investments, lp	6.4%	3,806,018	SC 13G/A
Feb 09, 2022	carmignac gestion	5.2%	3,124,252	SC 13G/A
Jan 24, 2022	whitmore bradford t	9.9%	5,878,197	SC 13G/A
Feb 12, 2021	rtw investments, lp	8.19%	3,958,130	SC 13G/A
Feb 12, 2021	carmignac gestion	7.3%	3,540,961	SC 13G

Recent SEC filings of Clearside Biomedical Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 19, 2024	4	Insider Trading
Apr 16, 2024	8-K	Current Report
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	3	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	3	Insider Trading

Peers (Alternatives to Clearside Biomedical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Clearside Biomedical Inc News

Latest updates

Clearside Biomedical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2017Q4
Revenue	638.6%	6,345	859	1,018	330	266	384	13,036	25,687	3,074	780	396	11.00	3,432	354	4,097	1,942	141	45.00	45.00	50.00	55.00
Operating Expenses	17.0%	9,260	7,913	8,288	8,400	6,990	8,221	7,993	6,980	7,963	6,876	8,383	7,121	5,864	5,911	6,933	4,955	6,509	5,662	15,351	21,662	-
S&GA Expenses	11.8%	2,947	2,637	3,127	3,169	2,353	2,791	3,457	3,140	2,816	2,816	2,893	2,649	2,374	2,611	3,122	3,650	3,781	5,004	4,384	4,176	-
R&D Expenses	23.0%	6,313	5,134	4,948	5,027	4,637	5,430	4,536	3,840	5,147	4,060	5,490	4,472	3,490	3,300	3,811	1,305	2,728	658	10,967	17,486	-
Net Income	47.9%	-4,832	-9,267	-9,106	-9,663	-7,827	-7,813	-7,644	18,709	-4,887	-6,095	-7,351	-7,112	-2,433	-5,754	-2,911	-3,096	-6,536	-5,734	-15,404	-21,638	-
Net Income Margin	74.8%	-3.80*	-15.09*	-17.96*	-24.83*	-0.55*	-0.11*	0.00*	0.01*	-1.05*	-1.23*	-1.70*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	105.8%	375	-6,520	-6,436	-5,698	-6,341	-5,443	3,871	5,054	-3,278	-6,950	-5,559	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.2%	34.00	34.00	39.00	45.00	51.00	56.00	31.00	36.00	43.00	27.00	29.00	28.00	19.00	17.00	18.00	25.00	27.00	26.00	30.00	38.00	44.00
Current Assets	-2.2%	30.00	31.00	36.00	43.00	49.00	55.00	30.00	35.00	42.00	27.00	28.00	27.00	18.00	16.00	16.00	24.00	25.00	24.00	28.00	35.00	43.00
Cash Equivalents	0.4%	29.00	29.00	35.00	41.00	48.00	53.00	29.00	34.00	30.00	25.00	26.00	26.00	17.00	15.00	15.00	21.00	23.00	23.00	26.00	33.00	8.00
Net PPE	13.4%	3.00	3.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	5.6%	50.00	47.00	44.00	42.00	41.00	37.00	5.00	4.00	5.00	10.00	9.00	11.00	11.00	9.00	10.00	15.00	16.00	16.00	17.00	21.00	21.00
Current Liabilities	16.8%	7.00	6.00	5.00	5.00	6.00	5.00	5.00	4.00	5.00	9.00	9.00	10.00	10.00	8.00	9.00	14.00	11.00	11.00	8.00	12.00	10.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	-	4.00	4.00	8.00	9.00	9.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	0.00	5.00	1.00	6.00	2.00	1.00	1.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	-	4.00	4.00	8.00	9.00	9.00
Shareholder's Equity	-Infinity%	-15.91	-	-	3.00	11.00	19.00	25.00	32.00	38.00	18.00	19.00	17.00	9.00	8.00	7.00	10.00	11.00	10.00	13.00	16.00	24.00
Retained Earnings	-1.5%	-320	-316	-306	-297	-288	-278	-270	-263	-255	-274	-269	-263	-255	-248	-246	-240	-237	-234	-228	-222	-206
Additional Paid-In Capital	0.6%	305	303	302	300	299	297	296	295	293	292	289	280	265	257	254	251	249	244	241	238	230
Shares Outstanding	1.2%	63.00	62.00	62.00	61.00	61.00	60.00	60.00	60.00	58.00	59.00	58.00	57.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	64.00	-	-	-	80.00	-	-	-	228	-	-	-	66.00	-	-	-	33.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	108.1%	495	-6,075	-5,339	-7,216	-5,607	-6,186	-5,443	3,871	5,054	-3,278	-6,950	-5,559	-4,436	-2,661	-3,220	-2,803	1,689	-6,047	-10,057	-12,653	-24,259
Share Based Compensation	-4.5%	1,026	1,074	1,061	1,041	1,149	1,074	1,354	1,307	1,253	1,316	1,331	1,154	867	841	891	1,001	1,139	970	1,256	1,247	1,162
Cashflow From Investing	73.0%	-120	-445	-1,097	-115	-91.00	-155	-	-	-	-	-	-	-	-110	110	-55.00	-	-	1,993	30,932	16,441
Cashflow From Financing	-181.1%	-257	317	22.00	332	575	30,689	4.00	65.00	165	2,081	7,117	14,419	6,884	-463	253	1,193	-1,645	2,424	1,288	6,628	20.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLSD Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
License and other revenue (includes $5,050 from a related party for the year ended December 31, 2023)	$ 8,226	$ 1,327	$ 29,575
Type of Revenue [Extensible List]	License [Member]	License [Member]	License [Member]
Operating expenses:
Cost of goods sold	$ 355	$ 204	$ 0
Research and development (includes $1,109 to a related party for the year ended December 31, 2023)	20,846	19,630	18,537
General and administrative	11,869	11,770	11,665
Total operating expenses	33,070	31,604	30,202
Loss from operations	(24,844)	(30,277)	(627)
Other income	1,719	669	1,003
Non-cash interest expense on liability related to the sales of future royalties	(9,360)	(3,339)	0
Net (loss) income	$ (32,485)	$ (32,947)	$ 376
Net (loss) income per share of common stock - basic	$ (0.53)	$ (0.55)	$ 0.01
Net (loss) income per share of common stock - diluted	$ (0.53)	$ (0.55)	$ 0.01
Weighted average shares outstanding - basic	61,806,959	60,204,862	58,491,986
Weighted average shares outstanding - diluted	61,806,959	60,204,862	59,906,602

CLSD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28,920	$ 48,258
Accounts receivable	170	0
Prepaid expenses	722	704
Other current assets	311	439
Total current assets	30,123	49,401
Property and equipment, net	2,996	755
Operating lease right-of-use asset	869	1,117
Other assets	30	30
Total assets	34,018	51,303
Current liabilities:
Accounts payable (includes $331 to a related party as of December 31, 2023)	2,205	1,050
Accrued liabilities (includes $215 to a related party as of December 31, 2023)	4,169	4,179
Current portion of operating lease liabilities	364	349
Deferred revenue	75	205
Total current liabilities	6,813	5,783
Liability related to the sales of future royalties, net	41,988	33,977
Operating lease liabilities	649	936
Other non-current liabilities	480	0
Total liabilities	49,930	40,696
Commitments and contingencies
Stockholders' (deficit) equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at December 31, 2023 and 2022	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022, respectively; 62,850,841 and 59,722,930 shares issued and outstanding at December 31, 2023 and 2022, respectively	63	61
Additional paid-in capital	304,948	298,984
Accumulated deficit	(320,923)	(288,438)
Total stockholders' (deficit) equity	(15,912)	10,607
Total liabilities and stockholders' (deficit) equity	$ 34,018	$ 51,303

About Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CEO	Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
WEBSITE	https://clearsidebio.com
INDUSTRY	Biotechnology
EMPLOYEES	36

Clearside Biomedical Inc Frequently Asked Questions

What is the ticker symbol for Clearside Biomedical Inc? What does CLSD stand for in stocks?

CLSD is the stock ticker symbol of Clearside Biomedical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clearside Biomedical Inc (CLSD)?

As of Fri May 03 2024, market cap of Clearside Biomedical Inc is 97.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLSD stock?

You can check CLSD's fair value in chart for subscribers.

What is the fair value of CLSD stock?

You can check CLSD's fair value in chart for subscribers. The fair value of Clearside Biomedical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Clearside Biomedical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLSD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Clearside Biomedical Inc a good stock to buy?

The fair value guage provides a quick view whether CLSD is over valued or under valued. Whether Clearside Biomedical Inc is cheap or expensive depends on the assumptions which impact Clearside Biomedical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLSD.

What is Clearside Biomedical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, CLSD's PE ratio (Price to Earnings) is -3.01 and Price to Sales (PS) ratio is 11.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLSD PE ratio will change depending on the future growth rate expectations of investors.